Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498218 | 0.86 | TSHR (0.59) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL5468755 | 0.81 | TSHR (0.53) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL28651663 | 0.79 | TSHR (0.52) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL12233265 | 0.79 | TSHR (0.52) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL1527656 | 0.79 | TSHR (0.39) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL4184254 | 0.78 | ALDH1A1 (0.56) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL17885225 | 0.78 | TSHR (0.50) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL18830973 | 0.78 | TSHR (0.50) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| SCHEMBL10761258 | 0.76 | TSHR (0.48) | TSHRALDH1A1HSD17B10GAAMAPK1 | |
| Hydrochloric Acid SCHEMBL1492019 | 0.76 | ALDH1A1 (0.54) | TSHRALDH1A1HSD17B10GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116917282-A | Amide derivatives and use thereof | 成都百裕制药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2022237781-A1 | AMIDE DERIVATIVE AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2022-11-17 | — | — | WO | disclosed |
| CN-107709334-B | Novel amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-04-13 | — | — | CN | disclosed |
| CN-108602841-B | Novel ammonium derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-03-23 | — | — | CN | disclosed |
| CN-107709333-B | Hydroxy ester derivatives, process for their preparation and pharmaceutical compositions containing them | 法国施维雅药厂 | 2021-01-01 | — | — | CN | disclosed |
| US-10711010-B2 | Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2020-07-14 | — | — | US | disclosed |
| EP-3313851-B1 | NEW HYDROXYESTER DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-11-06 | — | — | EP | disclosed |
| EP-3405471-B1 | NEW AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2019-10-30 | — | — | EP | disclosed |
| US-10457687-B2 | Aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-10-29 | — | — | US | disclosed |
| US-10457689-B2 | Ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-10-29 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| US-7662958-B2 | e.g. N-[3-{1-[(cyclobutyl)amino]-4-hydroxy-2-oxo-1,2-dihydro-quinolin -3-yl}-1,1-dioxo-1,4-dihydro-1 lambda 6-thieno[2,3-e][1,2,4]thiadiazin-7-yl)methyl]methane-sulfonamide; viricides for infections caused by an RNA-containing virus; hepatitis C virus (HCV) polymerase inhibitor; liver cirrhosis | ABBVIE INC. | 2010-02-16 | — | — | US | disclosed |
| WO-2009152166-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | ABBVIE INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008011337-A1 | HCV INHIBITORS | ABBOTT LABORATORIES (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711010-B2 | Hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | CASP3, BAX, CASP7 | TSHR 1099/4885ALDH1A1 588/4885HSD17B10 275/4885 |
| US-20080214528-A1 | ANTI-INFECTIVE AGENTS | NQO2, RSU1, RRS1 | TSHR 3202/4885ALDH1A1 1406/4885HSD17B10 2670/4885 |
| US-10457689-B2 | Ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | ARG1, ASS1, ATP6V1B1 | TSHR 1241/4885ALDH1A1 1905/4885HSD17B10 3857/4885 |
| US-10457687-B2 | Aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them | BAX, ARG2, ANXA5 | TSHR 2243/4885ALDH1A1 2999/4885HSD17B10 4447/4885 |
| US-20090306057-A1 | [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS | CYP2E1, CYP1A1, CYP1B1 | TSHR 2373/4885ALDH1A1 85/4885HSD17B10 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.